JP2024532729A5 - - Google Patents

Info

Publication number
JP2024532729A5
JP2024532729A5 JP2024507151A JP2024507151A JP2024532729A5 JP 2024532729 A5 JP2024532729 A5 JP 2024532729A5 JP 2024507151 A JP2024507151 A JP 2024507151A JP 2024507151 A JP2024507151 A JP 2024507151A JP 2024532729 A5 JP2024532729 A5 JP 2024532729A5
Authority
JP
Japan
Prior art keywords
optionally substituted
tautomer
compound
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/111129 external-priority patent/WO2023016447A1/en
Publication of JP2024532729A publication Critical patent/JP2024532729A/ja
Publication of JP2024532729A5 publication Critical patent/JP2024532729A5/ja
Pending legal-status Critical Current

Links

JP2024507151A 2021-08-09 2022-08-09 フェロトーシス調節物質、その調製及び使用 Pending JP2024532729A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/111481 2021-08-09
CN2021111481 2021-08-09
PCT/CN2022/111129 WO2023016447A1 (en) 2021-08-09 2022-08-09 Ferroptosis modulators, preparations, and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532729A JP2024532729A (ja) 2024-09-10
JP2024532729A5 true JP2024532729A5 (enExample) 2025-08-18

Family

ID=85199873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507151A Pending JP2024532729A (ja) 2021-08-09 2022-08-09 フェロトーシス調節物質、その調製及び使用

Country Status (7)

Country Link
US (1) US20240360114A1 (enExample)
EP (1) EP4384493A4 (enExample)
JP (1) JP2024532729A (enExample)
CN (1) CN118076581A (enExample)
CA (1) CA3227251A1 (enExample)
IL (1) IL310387A (enExample)
WO (1) WO2023016447A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1306450A (en) * 1970-08-22 1973-02-14 Pfizer Ltd Mono-alkyl-substituted diarylamino- and aryl-4-alkyl-benzyl-amino- alkylamines
JP3280040B2 (ja) * 1990-03-26 2002-04-30 武田薬品工業株式会社 アミノベンゼン化合物
SE0004054D0 (sv) * 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
SA08290668B1 (ar) * 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
US8227618B2 (en) * 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
US9580398B2 (en) * 2012-04-02 2017-02-28 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
EP3791870A1 (en) * 2013-12-02 2021-03-17 The Trustees of Columbia University in the City of New York Modulating ferroptosis and treating excitotoxic disorders
GB201420235D0 (en) * 2014-11-14 2014-12-31 Vib Vzw And Universiteit Antwerpen And Universiteit Gent Compounds for inhibiting cell death
WO2018109647A1 (en) * 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
AU2018300980A1 (en) * 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
ES3064093T3 (en) * 2017-10-20 2026-04-22 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2019106434A1 (en) * 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
WO2020113028A1 (en) * 2018-11-27 2020-06-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
WO2020185738A1 (en) * 2019-03-11 2020-09-17 Collaborative Medicinal Development, Llc Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders

Similar Documents

Publication Publication Date Title
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP2005522438A5 (enExample)
JP2024523697A5 (enExample)
RU2283835C3 (ru) Производные гетероциклических соединений и лекарственные средства
JP2017523972A5 (enExample)
JP2005505586A5 (enExample)
JP2003528070A (ja) 殺虫性アントラニルアミド類
JP2017504576A5 (enExample)
JP2004517925A5 (enExample)
JP2006524222A5 (enExample)
JP2011057661A (ja) 殺虫性カルボキサミド類
JP2005517672A5 (enExample)
JP2004534096A5 (enExample)
RU2001108494A (ru) Диазепановые производные или их соли
JP2020500869A5 (enExample)
EP0857171A2 (de) Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren
JP2008540574A5 (enExample)
AU7446600A (en) Novel diarylamide derivatives and use thereof as medicines
JP2011526594A5 (enExample)
HRP20230290T1 (hr) Derivati triazina za liječenje bolesti u vezi sa neurotrofinima
RU2006101541A (ru) Производные пиперазина и способ их применения
JP4782289B2 (ja) 農薬トリアジン誘導体
RU2001135802A (ru) Антагонисты рецептора брадикинина
RU2007122408A (ru) Производные тетралина и индана и их применение
JP2022527618A5 (enExample)